Corvus Pharmaceuticals, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 19, 2024. Corvus is a clinical-stage biopharmaceutical company with no approved products and no product-sales revenue.
Business context and pipeline
Corvus develops immune-modulating therapies for cancers and other diseases. Its lead candidate, soquelitinib, is in Phase 1/1b development for T-cell lymphoma; ciforadenant is being studied in a Phase 1b/2 renal-cell-cancer combination trial; and Corvus has paused plans for its own mupadolimab Phase 2 trial while prioritizing the other programs. Angel Pharmaceuticals is developing licensed candidates in greater China. Corvus held approximately 49.7% of Angel at year-end and accounts for the investment using the equity method.
Financial and operating metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $16.5 million | $24.5 million |
| General and administrative expense | $6.9 million | $8.1 million |
| Total operating expenses | $23.4 million | $32.6 million |
| Net loss | $27.0 million | $41.3 million |
| Basic and diluted loss per share | $0.56 | $0.89 |
| Net cash used in operating activities | $23.9 million | $27.0 million |
| Cash, cash equivalents and marketable securities at year-end | $27.1 million | $42.3 million |
| Total assets / total liabilities at year-end | $45.6 million / $6.9 million | $68.2 million / $12.1 million |
Gross profit and operating margins are not meaningful because the company has no product revenue. No conventional borrowings are disclosed; year-end liabilities included $1.4 million of current operating lease liability. The facility lease expires in January 2025.
Material changes versus 2022
- Net loss narrowed by $14.3 million, primarily as operating expenses fell by $9.2 million and Corvus’s equity-method loss from Angel declined by $4.7 million.
- R&D expense fell by $7.9 million. Mupadolimab program expense declined by $9.0 million as Corvus reduced its own development activity; soquelitinib expense increased by $1.5 million as work advanced.
- Cash and marketable securities decreased by $15.2 million. Corvus raised $7.8 million net through its at-the-market (ATM) stock program, issuing about 2.46 million shares.
Outlook, commentary, risks and unusual items
- Funding and going concern: Management says existing resources are expected to fund planned operations only through the fourth quarter of 2024 and are insufficient for at least 12 months from the filing date. Management and the auditor identify substantial doubt about the company’s ability to continue as a going concern. Corvus expects to seek additional financing; failure to raise capital could require delays, reductions or termination of development programs. The $41 million invested in Angel is not available to Corvus.
- Development plans: Corvus anticipated starting a potentially registrational Phase 3 soquelitinib trial in relapsed peripheral T-cell lymphoma in Q3 2024. The planned study would enroll 150 patients, compare soquelitinib with physician-selected belinostat or pralatrexate, and use progression-free survival as the primary endpoint. A placebo-controlled Phase 1 atopic-dermatitis study was anticipated to start in Q2 2024. Ciforadenant RCC interim data were anticipated in 2024. These are forward-looking plans, not reported outcomes.
- Clinical data: In the Phase 1/1b soquelitinib study, the company reported an objective response rate of 33.3% among 21 evaluable patients at the 200 mg twice-daily dose as of January 22, 2024, including four complete and three partial responses. This cutoff is after fiscal year-end; the results are interim and not from a head-to-head comparison.
- Key risks: Clinical and regulatory outcomes are uncertain; the company relies on third parties for trials and manufacturing; financing needs may result in dilution or unfavorable terms; and competition, enrollment, supply, intellectual-property, reimbursement and regulatory risks could delay or limit development. Corvus has no commercial manufacturing or sales infrastructure.
- Other disclosures: The FDA granted soquelitinib Orphan Drug Designation for T-cell lymphoma on February 8, 2024. Corvus reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls and internal control over financial reporting.
Most important facts for investors to verify
- Whether Corvus secures sufficient financing to extend its runway, and the resulting dilution or other financing terms.
- Whether the planned Phase 3 soquelitinib trial starts on schedule, is adequately funded and produces confirmatory results; verify the protocol, endpoints and comparator details.
- Updated, audited soquelitinib efficacy and safety data, including response durability and results across patient subgroups; distinguish interim findings from final results.
- Progress and data from the ciforadenant trial, and the timing and scope of Corvus’s own mupadolimab development.
- Angel’s development progress and financial position, and the practical value of Corvus’s minority ownership and China licensing arrangements.